Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adult ileocolic intussusception with lymphoma as the lead point: a case report.

Journal of surgical case reports·2026

Same author

Composite Meshes: A Comprehensive Review of Materials, Biomechanics, Clinical Outcomes, and Emerging Innovations.

Cureus·2026

Same author

Spermatic Cord Lipomas: A Comprehensive Review of Diagnosis, Surgical Management, and Differential Considerations.

World journal of surgery·2026

Same author

Renal-Limited Thrombotic Microangiopathy due to Anti-VEGF/TKI Immunotherapy for Metastatic Renal Cell Carcinoma Presenting as Nephrotic Syndrome: A Case Report and Literature Review.

Clinical case reports·2026

Same author

Probing the Cancer Mutational Landscape of KMT2 Regulatory Subunits.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Same author

Antibody-drug conjugates for bladder sparing: lessons from SURE-02 trial.

The Lancet. Oncology·2026

Search research articles

Related Experiment Video

Updated: Apr 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Immunotherapy in Bladder Cancer.

Monali Vasekar, David Degraff, Monika Joshi¹

¹Penn State Hershey Cancer Institute, Department of Medicine, Mail Code CH046, 500 University Dr, Hershey, PA 17033, USA. mjoshi@hmc.psu.edu.

Current Molecular Pharmacology

|July 17, 2015

Summary

This summary is machine-generated.

Immunotherapy, including Bacille Calmette Guerin (BCG), has long been used for bladder cancer. Newer targeted immunotherapies offer more effective and personalized treatment options for this disease.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Related Experiment Videos

Last Updated: Apr 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Area of Science:

Oncology
Immunology

Background:

Bladder cancer treatment historically utilized immunotherapy with Bacille Calmette Guerin (BCG).
Chemotherapy for bladder cancer often causes unacceptable side effects and lacks durable responses.
Advances in understanding bladder cancer carcinogenesis enable targeted therapeutic strategies.

Purpose of the Study:

To review current and emerging immunotherapies for bladder cancer.
To discuss the therapeutic potential of both non-targeted and targeted immunotherapeutic agents.
To highlight novel approaches in managing localized or metastatic bladder cancer.

Main Methods:

Review of existing literature on bladder cancer immunotherapy.
Analysis of the mechanisms of action for various immunotherapeutic agents.
Focus on targeted immunotherapies, including CTLA-4 and PD-1 pathway inhibitors.

Main Results:

Non-targeted agents like BCG, interferons, and interleukins have a role in bladder cancer treatment.
Targeted immunotherapies, such as CTLA-4 and PD-1 pathway blockers, show significant therapeutic potential.
These targeted agents offer personalized treatment avenues for bladder cancer.

Conclusions:

Immunotherapy remains a cornerstone in bladder cancer management.
Targeted immunotherapies represent a significant advancement, offering improved efficacy and personalization.
Emerging immunotherapeutic strategies are expanding treatment options for bladder cancer patients.